Prucalopride Succinate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319934

CAS#: 179474-85-2 (Succinate)

Description: Prucalopride is a 5-HT4R agonist.


Chemical Structure

img
Prucalopride Succinate
CAS# 179474-85-2 (Succinate)

Theoretical Analysis

MedKoo Cat#: 319934
Name: Prucalopride Succinate
CAS#: 179474-85-2 (Succinate)
Chemical Formula: C22H32ClN3O7
Exact Mass: 0.00
Molecular Weight: 485.960
Elemental Analysis: C, 54.38; H, 6.64; Cl, 7.29; N, 8.65; O, 23.05

Price and Availability

Size Price Availability Quantity
50g USD -1
100mg USD 250
200mg USD 350
500mg USD 550
1g USD 950
2g USD 1450
5g USD 2250
10g USD 3950
20g USD 5450
Bulk inquiry

Related CAS #: 179474-85-2 (Succinate)   179474-81-8 (free base)   179474-80-7 (HCl)    

Synonym: R-108512; R 108512; R108512; R 093877; R-093877; R093877; R 93877; R-93877; R93877; Prucalopride Succinate; Resolor; Resotran; Motegrity;

IUPAC/Chemical Name: 4-amino-5-chloro-N-(1-(3-methoxypropyl)piperidin-4-yl)-2,3-dihydrobenzofuran-7-carboxamide succinate

InChi Key: QZRSNVSQLGRAID-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H26ClN3O3.C4H6O4/c1-24-9-2-6-22-7-3-12(4-8-22)21-18(23)14-11-15(19)16(20)13-5-10-25-17(13)14;5-3(6)1-2-4(7)8/h11-12H,2-10,20H2,1H3,(H,21,23);1-2H2,(H,5,6)(H,7,8)

SMILES Code: O=C(O)CCC(O)=O.O=C(C1=C(OCC2)C2=C(N)C(Cl)=C1)NC3CCN(CCCOC)CC3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 485.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548650/ PubMed PMID: 31643961.

2: Tameez Ud Din A, Khan AH, Bajwa H, Maqsood MH, Malik MN. Clinical Efficacy and Safety Profile of Prucalopride in Chronic Idiopathic Constipation. Cureus. 2019 Apr 4;11(4):e4382. doi: 10.7759/cureus.4382. Review. PubMed PMID: 31218146; PubMed Central PMCID: PMC6553670.

3: Vijayvargiya P, Camilleri M. Use of prucalopride in adults with chronic idiopathic constipation. Expert Rev Clin Pharmacol. 2019 Jul;12(7):579-589. doi: 10.1080/17512433.2019.1620104. Epub 2019 May 23. Review. PubMed PMID: 31096799.

4: Bassotti G, Usai Satta P, Bellini M. Prucalopride for the treatment of constipation: a view from 2015 and beyond. Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):257-262. doi: 10.1080/17474124.2019.1568238. Epub 2019 Jan 23. Review. PubMed PMID: 30791758.

5: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK536695/ PubMed PMID: 30694627.

6: Ho C, Severn M. Prucalopride for Gastrointestinal Motility Disorders: A Review of Clinical Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Dec 6. Available from http://www.ncbi.nlm.nih.gov/books/NBK526294/ PubMed PMID: 30260606.

7: Omer A, Quigley EMM. An update on prucalopride in the treatment of chronic constipation. Therap Adv Gastroenterol. 2017 Nov;10(11):877-887. doi: 10.1177/1756283X17734809. Epub 2017 Oct 16. Review. PubMed PMID: 29147138; PubMed Central PMCID: PMC5673021.

8: Smart CJ, Malik KI. Prucalopride for the treatment of ileus. Expert Opin Investig Drugs. 2017 Apr;26(4):489-493. doi: 10.1080/13543784.2017.1301427. Epub 2017 Mar 10. Review. PubMed PMID: 28277883.

9: Shin A. Patient considerations in the management of chronic constipation: focus on prucalopride. Patient Prefer Adherence. 2016 Jul 28;10:1373-84. doi: 10.2147/PPA.S92550. eCollection 2016. Review. PubMed PMID: 27528801; PubMed Central PMCID: PMC4970632.

10: Bellini M, Gambaccini D, Bassotti G. Prucalopride: For functional constipation only? Tech Coloproctol. 2016 Jul;20(7):433-6. doi: 10.1007/s10151-016-1477-8. Epub 2016 May 12. Review. PubMed PMID: 27174045.

11: Bassotti G, Gambaccini D, Bellini M. Prucalopride succinate for the treatment of constipation: an update. Expert Rev Gastroenterol Hepatol. 2016;10(3):291-300. doi: 10.1586/17474124.2016.1129897. Epub 2016 Jan 29. Review. PubMed PMID: 26647167.

12: Garnock-Jones KP. Prucalopride: A Review in Chronic Idiopathic Constipation. Drugs. 2016 Jan;76(1):99-110. doi: 10.1007/s40265-015-0518-3. Review. PubMed PMID: 26628294.

13: Diederen K, Mugie SM, Benninga MA. Efficacy and safety of prucalopride in adults and children with chronic constipation. Expert Opin Pharmacother. 2015 Feb;16(3):407-16. doi: 10.1517/14656566.2015.996547. Epub 2014 Dec 24. Review. PubMed PMID: 25539475.

14: Retraction: "Chronic constipation-associated symptoms in Asians and non-Asians, and effects of 12-week prucalopride treatment: A pooled analysis of 4 randomized, placebo-controlled trials" by Suck Chei CHOI, Duo Wu ZOU, Mei Yun KE, Somchai LEELAKUSOLVONG, Jan TACK, Eamonn MM QUIGLEY, Andy LIU and Jin Yong KIM. J Dig Dis. 2016 Apr;17(4):277. doi: 10.1111/1751-2980.12219. Review. PubMed PMID: 25495559.

15: Bellacosa L, Cogliandro R, Cremon C, De Giorgio R, Barbara G, Stanghellini V. [Some practical questions on chronic stipsis treatment with prucalopride]. Minerva Gastroenterol Dietol. 2014 Mar;60(1):85-99. Review. Italian. PubMed PMID: 24632771.

16: Shin A, Camilleri M, Kolar G, Erwin P, West CP, Murad MH. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther. 2014 Feb;39(3):239-53. doi: 10.1111/apt.12571. Epub 2013 Dec 5. Review. PubMed PMID: 24308797.

17: Keating GM. Prucalopride: a review of its use in the management of chronic constipation. Drugs. 2013 Nov;73(17):1935-50. doi: 10.1007/s40265-013-0140-1. Review. PubMed PMID: 24194435.

18: Tack J, Corsetti M. Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation. Expert Opin Drug Metab Toxicol. 2012 Oct;8(10):1327-35. doi: 10.1517/17425255.2012.719497. Review. PubMed PMID: 22985444.

19: Pennant M, Orlando R, Barton P, Bayliss S, Routh K, Meads C. Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief. Health Technol Assess. 2011 May;15 Suppl 1:43-50. doi: 10.3310/hta15suppl1/05. Review. PubMed PMID: 21609652.

20: What role for prucalopride in constipation? Drug Ther Bull. 2011 Aug;49(8):93-6. doi: 10.1136/dtb.2011.02.0050. Review. PubMed PMID: 21831905.